Arlene Siefker-Radtke, MD of @MDAndersonNews discusses the phase 1b/2 NORSE study on the treatment of metastatic urothelial carcinoma in patients…
Browsing: Prostate
Nima Sharifi, MD @nimasharifimd of @CleClinicMD @ClevelandClinic discusses HSD3B1(1245C) – how this affects clinicians and treatment today. _________ In a…
Nima Sharifi, MD @nimasharifimd of @CleClinicMD @ClevelandClinic answers common questions between genetic variant and poor outcomes in men with metastatic…
Nima Sharifi, MD @nimasharifimd of @CleClinicMD @ClevelandClinic discusses a link between genetic variant and poor outcomes in men with metastatic…
Two-drug combination effective in lab studies against aggressive prostate tumors Research team identifies new approach to treating prostate cancer Metabolic…
In a new Cleveland Clinic-led study published in JAMA Oncology, researchers show that a testosterone-related genetic variant – HSD3B1(1245C) – is associated with…
First time findings published in Nucleic Acids Research demonstrate the ability to differentiate exosomes from cancer cell subtypes from the…
Soumyajit Roy, MBBS @SouMyajiT_RO of University of Ottawa Division of Radiation Oncology, Department of Radiology discusses the impact of therapy…
Soumyajit Roy, MBBS @SouMyajiT_RO of University of Ottawa Division of Radiation Oncology, Department of Radiology discusses the impact of therapy…
Soumyajit Roy, MBBS @SouMyajiT_RO of University of Ottawa Division of Radiation Oncology, Department of Radiology discusses androgen-deprivation therapy with external-beam…
Soumyajit Roy, MBBS @SouMyajiT_RO of University of Ottawa Division of Radiation Oncology, Department of Radiology discusses androgen-deprivation therapy with external-beam…
Androgen Deprivation Therapy (ADT) for Men with Prostate Cancer GRACE is very excited to bring to more info from our…
Study results support development of LRIG1 as novel anti-cancer therapeutic Study is first to report that LRIG1 suppresses prostate cancer…
Primary efficacy endpoint met with 96.7% of men achieving sustained testosterone suppression to castrate levels (< 50 ng/dL) through 48…
Neal Shore, MD of Carolina Urologic Research Center @UrologyUS on how the ProVent trial might change the AS treatment landscape.…
Neal Shore, MD of Carolina Urologic Research Center @UrologyUS on how the ProVent trial might change the AS treatment landscape.…
Neal Shore, MD of Carolina Urologic Research Center @UrologyUS on how the ProVent trial might change the AS treatment landscape.…
Neal Shore, MD of Carolina Urologic Research Center @UrologyUS provides insight on current treatment options for men in the phase…
Neal Shore, MD of Carolina Urologic Research Center @UrologyUS discusses the phase 3 provent clinical trial. ____________ Dendreon Pharmaceuticals, a…
Douglas G. McNeel, MD of @UWCarbone discusses the phase II trial of a DNA vaccine encoding in patients with nonmetastatic,…
– Target Enrollment of 450 Achieved Early Due to High Demand – – Topline Results Expected in 2023 – Dendreon…
Douglas G. McNeel, MD of @UWCarbone discusses the phase II trial of a DNA vaccine encoding in patients with nonmetastatic,…
A research study published in Neoplasia, led by lead researcher Nallasivam Palanisamy, Ph.D., associate researcher at the Vattikuti Urology Institute…
Nallasivam Palanisamy, Ph.D. @NallasivamPala4 of @HenryFordNews highlights select biomarkers in patients with prostate cancer and what is next on the…
Nallasivam Palanisamy, Ph.D. @NallasivamPala4 of @HenryFordNews explains a unique biomarker can be detected in the urine samples of prostate cancer…
Nallasivam Palanisamy, Ph.D. @NallasivamPala4 of @HenryFordNews explains a biomarker in urine may offer noninvasive detection of prostate cancer. __________ A…
Sarah Osman of @Queens_Belfast explains the standardized technique is using CT scans to assess and predict prostate cancers in patients.…
Sarah Osman of @Queens_Belfast provides insight on research that found a new way to predict the future behavior of prostate…
Sarah Osman of @Queens_Belfast provides insight on research that found a new way to predict the future behavior of prostate…
Researchers from Queen’s University Belfast have discovered a new way to predict the aggressiveness and future behaviour of prostate cancers.…
An international panel of experts will identify the best approaches to implement genetic testing for men with prostate cancer  …
Data published today in the New England Journal of Medicine showed that patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with…
Results from the second interim analysis of the Phase 3 SPARTAN study featured in an oral presentation at ESMO 2019…
Shauna Campbell, MD of Cleveland Clinic explains the impact of post-prostatectomy prostate specific antigen (PSA) kinetics on outcomes of salvage…
Sarmad Sadeghi, MD of USC Norris Comprehensive Cancer Center explains awaiting approval from the FDA in bladder and prostate cancer.
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai explains the results of…
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai shares details on upcoming…
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai elaborates on how biomarker…
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai explains the differences between…
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai discusses the outcomes of…
Nancy A. Dawson MD, Professor of Medicine at Lombardi Cancer Center elaborates on the preferred agents on the 2nd line…
Nancy A. Dawson MD, Professor of Medicine at Lombardi Cancer Center shares on how to decide between combinations of immuno-oncology…
Nancy A. Dawson MD, Professor of Medicine at Lombardi Cancer Center shares the TITAN Study outcomes, investigating apalutamide in metastatic…
Nancy A Dawson MD, Professor of Medicine at Lombardi Cancer Center discusses her view on the ENZAMET Study while comparing…
Kim Chi MD, Medical Oncologist, Senior Scientist at the BC Cancer Agency elaborates on the importance of biomarker selection trials.…
Kim Chi MD, Medical Oncologist, Senior Scientist at the BC Cancer Agency explains what came out of the metastatic castration-sensitive…
Scott Tagawa MD @drscottagawa Of Weill Cornell Medicine and NewYork-Presbyterian Discusses Some That Image Well Do Not Respond: BRCA2 Is…
Scott Tagawa MD @drscottagawa Of Weill Cornell Medicine and NewYork-Presbyterian Discusses If They Are Imaging Negative, How Are They Responding:…
Scott Tagawa MD @drscottagawa Of Weill Cornell Medicine and NewYork-Presbyterian Discusses Targeting PSMA: Patients That Have At Least One Bright…
Mark Fleming MD Of US Oncology Research Discusses Treatment Sequencing For Castrate Resistant M0 Disease: Looking At 3 Drugs Enzalutamide,…